{
    "doc_id": "mmlu_224_deepseek-ai_DeepSeek-R1",
    "metadata": {
        "model_id": "deepseek-ai/DeepSeek-R1",
        "subject": "nutrition",
        "correct_answer": "Metformin"
    },
    "raw_text": {
        "question": "What is the first-line drug for patients with type 2 diabetes and obesity, as of 2020?\n",
        "response": "Okay, so I need to figure out the first-line drug for patients with type 2 diabetes and obesity as of 2020. Let me start by recalling what I know about diabetes medications. Type 2 diabetes is often associated with obesity, so the treatment should ideally address both conditions. \n\nFirst, I remember that metformin has traditionally been the first-line medication for type 2 diabetes. It's been around for a while and is effective in lowering blood glucose levels. But does it help with weight loss? I think metformin can sometimes cause weight loss or be weight-neutral, but maybe not as effective as other drugs specifically targeting weight.\n\nThen there are newer classes of medications like GLP-1 receptor agonists and SGLT2 inhibitors. GLP-1 agonists, such as liraglutide or semaglutide, I believe they help with blood sugar control and also promote weight loss. I've heard that drugs like Ozempic (semaglutide) are used for diabetes and can lead to significant weight loss. Similarly, SGLT2 inhibitors like empagliflozin or dapagliflozin help the kidneys excrete more glucose, which also leads to some weight loss, though maybe not as much as GLP-1 agonists.\n\nBut the question is about the first-line drug as of 2020. Guidelines might have changed. I recall that the American Diabetes Association (ADA) updates their standards of care annually. In recent years, there's been a shift towards considering comorbidities. For patients with type 2 diabetes and obesity, cardiovascular disease, or heart failure, the guidelines might recommend GLP-1 agonists or SGLT2 inhibitors even before metformin. Wait, no, I think metformin is still first-line, but for those with specific conditions, those other drugs are added early.\n\nWait, but if the patient has obesity, maybe the preference is for a drug that also aids in weight loss. So perhaps GLP-1 agonists are recommended as first-line in such cases. Let me check. The ADA's 2020 guidelines might say that for patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease, a GLP-1 agonist or SGLT2 inhibitor with proven benefit should be considered. But for those without those conditions but with obesity, maybe GLP-1 agonists are preferred over metformin?\n\nAlternatively, maybe metformin is still first-line, but when obesity is a concern, adding a GLP-1 agonist early on is recommended. But the question is about first-line, so the initial drug choice. I need to confirm whether ADA or other guidelines have updated their recommendations to prioritize GLP-1 agonists over metformin in obese patients.\n\nLooking up, in the ADA 2020 Standards of Care, section 9. Pharmacologic Approaches to Glycemic Treatment. It states that metformin is the preferred initial pharmacologic agent for type 2 diabetes. However, in patients with established ASCVD, indicators of high risk, heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit is recommended as part of the initial therapy. For patients with type 2 diabetes who are overweight or obese, consider selecting anti-hyperglycemic medications that promote weight loss. Metformin is weight-neutral or modest weight loss, while GLP-1 agonists and SGLT2 inhibitors can offer more significant weight loss. \n\nSo, if the patient has both type 2 diabetes and obesity, even without cardiovascular issues, the guidelines might suggest using GLP-1 agonists or SGLT2 inhibitors as first-line, but I think metformin is still the first-line unless there are specific comorbidities. However, some sources might argue that in obese patients, starting with a GLP-1 agonist first could be better for weight management. But the official ADA guidelines as of 2020 still recommend metformin as first-line, with consideration of adding or switching to GLP-1 agonists if there's a need for weight loss or cardiovascular benefits.\n\nWait, but maybe there's a specific drug approved for both diabetes and obesity. For example, liraglutide (Victoza) is a GLP-1 agonist for diabetes, and Saxenda is liraglutide for obesity. Similarly, semaglutide (Ozempic for diabetes, Wegovy for obesity). So in a patient with both conditions, using a GLP-1 agonist might be appropriate as first-line. But does the guideline explicitly say that?\n\nAnother angle: the 2020 ADA guidelines mention that for patients with type 2 diabetes who are obese, weight management is a critical part of treatment. They recommend that pharmacotherapy for weight loss should be considered in such patients. However, the first-line for glycemic control is still metformin. But if the patient needs both glycemic control and weight loss, then GLP-1 agonists might be preferred. So perhaps in the context of obesity, GLP-1 agonists are considered first-line alongside metformin, or even instead of metformin.\n\nWait, the ADA's 2020 guidelines state that metformin remains the first-line therapy unless contraindicated. However, in patients where weight loss is a priority, GLP-1 receptor agonists or SGLT2 inhibitors may be appropriate even as initial therapy. So maybe the answer is that for patients with type 2 diabetes and obesity, the first-line drug is metformin, but GLP-1 agonists are recommended as first-line in conjunction with metformin or when weight loss is a primary concern.\n\nAlternatively, some guidelines from other organizations, like the American Association of Clinical Endocrinologists (AACE), might have different recommendations. For example, AACE guidelines might prioritize GLP-1 agonists more in obese patients. But the question is as of 2020, so I need to check the most recent guidelines around that time.\n\nLooking up, ADA 2020 guidelines: For patients with T2D and overweight/obesity, first-line therapy includes lifestyle modifications plus metformin. If HbA1c is above target, then adding GLP-1 or SGLT2 inhibitors. However, if the patient has compelling needs for weight loss, then GLP-1 agonists may be considered earlier. But as first-line, metformin is still the initial drug. So the answer would be metformin, but with consideration of GLP-1 agonists if weight loss is a priority.\n\nBut maybe there's a nuance here. For example, in patients with high cardiovascular risk, GLP-1 agonists are recommended. But for obesity without other comorbidities, metformin is still first-line. However, given that obesity itself is a comorbidity, perhaps the guidelines have shifted. Wait, ADA 2020 does mention that in patients with type 2 diabetes and obesity, medications that promote weight loss (like GLP-1 agonists) should be considered. But does that mean they are first-line instead of metformin?\n\nAlternatively, maybe the combination of metformin plus a GLP-1 agonist is first-line. But typically, first-line refers to the initial monotherapy. So if the patient is newly diagnosed, the first drug would be metformin. If they have obesity, then adding a GLP-1 agonist early on. But the question is about the first-line drug, so monotherapy.\n\nAnother point: some sources suggest that in obese patients with type 2 diabetes, GLP-1 agonists may be preferred as first-line due to their weight loss benefits. However, metformin is cheaper and has a long safety record, so it's still first-line. But guidelines might differ based on specific patient factors.\n\nIn summary, the answer might be that as of 2020, metformin is still the first-line drug for type 2 diabetes, including in patients with obesity. However, GLP-1 receptor agonists are recommended as first-line in patients where weight loss is a priority or when there's established cardiovascular disease. But the exact first-line might depend on the specific guidelines followed. The ADA 2020 Standards of Care state that metformin is first-line, but GLP-1 agonists are preferred if there's a compelling need for weight loss or cardiovascular benefits."
    },
    "nodes": [
        {
            "id": "ctx0",
            "annotation": false,
            "start": 0,
            "end": 87,
            "label": "context",
            "text": "What is the first-line drug for patients with type 2 diabetes and obesity, as of 2020?\n",
            "source": "question"
        },
        {
            "id": "resp0",
            "annotation": false,
            "start": 0,
            "end": 108,
            "label": "restatement",
            "text": "Okay, so I need to figure out the first-line drug for patients with type 2 diabetes and obesity as of 2020. ",
            "source": "response"
        },
        {
            "id": "resp1",
            "annotation": false,
            "start": 108,
            "end": 174,
            "label": "planning",
            "text": "Let me start by recalling what I know about diabetes medications. ",
            "source": "response"
        },
        {
            "id": "resp2",
            "annotation": false,
            "start": 174,
            "end": 283,
            "label": "reasoning",
            "text": "Type 2 diabetes is often associated with obesity, so the treatment should ideally address both conditions. \n\n",
            "source": "response"
        },
        {
            "id": "resp3",
            "annotation": false,
            "start": 283,
            "end": 386,
            "label": "fact",
            "text": "First, I remember that metformin has traditionally been the first-line medication for type 2 diabetes. ",
            "source": "response"
        },
        {
            "id": "resp4",
            "annotation": false,
            "start": 386,
            "end": 466,
            "label": "fact",
            "text": "It's been around for a while and is effective in lowering blood glucose levels. ",
            "source": "response"
        },
        {
            "id": "resp5",
            "annotation": false,
            "start": 466,
            "end": 501,
            "label": "reflection",
            "text": "But does it help with weight loss? ",
            "source": "response"
        },
        {
            "id": "resp6",
            "annotation": false,
            "start": 501,
            "end": 647,
            "label": "reasoning",
            "text": "I think metformin can sometimes cause weight loss or be weight-neutral, but maybe not as effective as other drugs specifically targeting weight.\n\n",
            "source": "response"
        },
        {
            "id": "resp7",
            "annotation": false,
            "start": 647,
            "end": 742,
            "label": "fact",
            "text": "Then there are newer classes of medications like GLP-1 receptor agonists and SGLT2 inhibitors. ",
            "source": "response"
        },
        {
            "id": "resp8",
            "annotation": false,
            "start": 742,
            "end": 869,
            "label": "fact",
            "text": "GLP-1 agonists, such as liraglutide or semaglutide, I believe they help with blood sugar control and also promote weight loss. ",
            "source": "response"
        },
        {
            "id": "resp9",
            "annotation": false,
            "start": 869,
            "end": 981,
            "label": "fact",
            "text": "I've heard that drugs like Ozempic (semaglutide) are used for diabetes and can lead to significant weight loss. ",
            "source": "response"
        },
        {
            "id": "resp10",
            "annotation": false,
            "start": 981,
            "end": 1167,
            "label": "fact",
            "text": "Similarly, SGLT2 inhibitors like empagliflozin or dapagliflozin help the kidneys excrete more glucose, which also leads to some weight loss, though maybe not as much as GLP-1 agonists.\n\n",
            "source": "response"
        },
        {
            "id": "resp11",
            "annotation": false,
            "start": 1167,
            "end": 1225,
            "label": "restatement",
            "text": "But the question is about the first-line drug as of 2020. ",
            "source": "response"
        },
        {
            "id": "resp12",
            "annotation": false,
            "start": 1225,
            "end": 1256,
            "label": "reflection",
            "text": "Guidelines might have changed. ",
            "source": "response"
        },
        {
            "id": "resp13",
            "annotation": false,
            "start": 1256,
            "end": 1352,
            "label": "fact",
            "text": "I recall that the American Diabetes Association (ADA) updates their standards of care annually. ",
            "source": "response"
        },
        {
            "id": "resp14",
            "annotation": false,
            "start": 1352,
            "end": 1425,
            "label": "reasoning",
            "text": "In recent years, there's been a shift towards considering comorbidities. ",
            "source": "response"
        },
        {
            "id": "resp15",
            "annotation": false,
            "start": 1425,
            "end": 1603,
            "label": "reasoning",
            "text": "For patients with type 2 diabetes and obesity, cardiovascular disease, or heart failure, the guidelines might recommend GLP-1 agonists or SGLT2 inhibitors even before metformin. ",
            "source": "response"
        },
        {
            "id": "resp16",
            "annotation": false,
            "start": 1603,
            "end": 1728,
            "label": "reflection",
            "text": "Wait, no, I think metformin is still first-line, but for those with specific conditions, those other drugs are added early.\n\n",
            "source": "response"
        },
        {
            "id": "resp17",
            "annotation": false,
            "start": 1728,
            "end": 1832,
            "label": "reflection",
            "text": "Wait, but if the patient has obesity, maybe the preference is for a drug that also aids in weight loss. ",
            "source": "response"
        },
        {
            "id": "resp18",
            "annotation": false,
            "start": 1832,
            "end": 1903,
            "label": "reasoning",
            "text": "So perhaps GLP-1 agonists are recommended as first-line in such cases. ",
            "source": "response"
        },
        {
            "id": "resp19",
            "annotation": false,
            "start": 1903,
            "end": 1917,
            "label": "planning",
            "text": "Let me check. ",
            "source": "response"
        },
        {
            "id": "resp20",
            "annotation": false,
            "start": 1917,
            "end": 2175,
            "label": "fact",
            "text": "The ADA's 2020 guidelines might say that for patients with type 2 diabetes and established atherosclerotic cardiovascular disease (ASCVD), heart failure, or chronic kidney disease, a GLP-1 agonist or SGLT2 inhibitor with proven benefit should be considered. ",
            "source": "response"
        },
        {
            "id": "resp21",
            "annotation": false,
            "start": 2175,
            "end": 2284,
            "label": "reasoning",
            "text": "But for those without those conditions but with obesity, maybe GLP-1 agonists are preferred over metformin?\n\n",
            "source": "response"
        },
        {
            "id": "resp22",
            "annotation": false,
            "start": 2284,
            "end": 2415,
            "label": "reasoning",
            "text": "Alternatively, maybe metformin is still first-line, but when obesity is a concern, adding a GLP-1 agonist early on is recommended. ",
            "source": "response"
        },
        {
            "id": "resp23",
            "annotation": false,
            "start": 2415,
            "end": 2481,
            "label": "restatement",
            "text": "But the question is about first-line, so the initial drug choice. ",
            "source": "response"
        },
        {
            "id": "resp24",
            "annotation": false,
            "start": 2481,
            "end": 2630,
            "label": "planning",
            "text": "I need to confirm whether ADA or other guidelines have updated their recommendations to prioritize GLP-1 agonists over metformin in obese patients.\n\n",
            "source": "response"
        },
        {
            "id": "resp25",
            "annotation": false,
            "start": 2630,
            "end": 2736,
            "label": "planning",
            "text": "Looking up, in the ADA 2020 Standards of Care, section 9. Pharmacologic Approaches to Glycemic Treatment. ",
            "source": "response"
        },
        {
            "id": "resp26",
            "annotation": false,
            "start": 2736,
            "end": 2827,
            "label": "fact",
            "text": "It states that metformin is the preferred initial pharmacologic agent for type 2 diabetes. ",
            "source": "response"
        },
        {
            "id": "resp27",
            "annotation": false,
            "start": 2827,
            "end": 3065,
            "label": "fact",
            "text": "However, in patients with established ASCVD, indicators of high risk, heart failure, or chronic kidney disease, a GLP-1 receptor agonist or SGLT2 inhibitor with proven cardiovascular benefit is recommended as part of the initial therapy. ",
            "source": "response"
        },
        {
            "id": "resp28",
            "annotation": false,
            "start": 3065,
            "end": 3204,
            "label": "fact",
            "text": "For patients with type 2 diabetes who are overweight or obese, consider selecting anti-hyperglycemic medications that promote weight loss. ",
            "source": "response"
        },
        {
            "id": "resp29",
            "annotation": false,
            "start": 3204,
            "end": 3339,
            "label": "fact",
            "text": "Metformin is weight-neutral or modest weight loss, while GLP-1 agonists and SGLT2 inhibitors can offer more significant weight loss. \n\n",
            "source": "response"
        },
        {
            "id": "resp30",
            "annotation": false,
            "start": 3339,
            "end": 3604,
            "label": "reasoning",
            "text": "So, if the patient has both type 2 diabetes and obesity, even without cardiovascular issues, the guidelines might suggest using GLP-1 agonists or SGLT2 inhibitors as first-line, but I think metformin is still the first-line unless there are specific comorbidities. ",
            "source": "response"
        },
        {
            "id": "resp31",
            "annotation": false,
            "start": 3604,
            "end": 3737,
            "label": "reasoning",
            "text": "However, some sources might argue that in obese patients, starting with a GLP-1 agonist first could be better for weight management. ",
            "source": "response"
        },
        {
            "id": "resp32",
            "annotation": false,
            "start": 3737,
            "end": 3944,
            "label": "restatement",
            "text": "But the official ADA guidelines as of 2020 still recommend metformin as first-line, with consideration of adding or switching to GLP-1 agonists if there's a need for weight loss or cardiovascular benefits.\n\n",
            "source": "response"
        },
        {
            "id": "resp33",
            "annotation": false,
            "start": 3944,
            "end": 4024,
            "label": "reflection",
            "text": "Wait, but maybe there's a specific drug approved for both diabetes and obesity. ",
            "source": "response"
        },
        {
            "id": "resp34",
            "annotation": false,
            "start": 4024,
            "end": 4132,
            "label": "fact",
            "text": "For example, liraglutide (Victoza) is a GLP-1 agonist for diabetes, and Saxenda is liraglutide for obesity. ",
            "source": "response"
        },
        {
            "id": "resp35",
            "annotation": false,
            "start": 4132,
            "end": 4199,
            "label": "fact",
            "text": "Similarly, semaglutide (Ozempic for diabetes, Wegovy for obesity). ",
            "source": "response"
        },
        {
            "id": "resp36",
            "annotation": false,
            "start": 4199,
            "end": 4295,
            "label": "reasoning",
            "text": "So in a patient with both conditions, using a GLP-1 agonist might be appropriate as first-line. ",
            "source": "response"
        },
        {
            "id": "resp37",
            "annotation": false,
            "start": 4295,
            "end": 4340,
            "label": "reflection",
            "text": "But does the guideline explicitly say that?\n\n",
            "source": "response"
        },
        {
            "id": "resp38",
            "annotation": false,
            "start": 4340,
            "end": 4492,
            "label": "fact",
            "text": "Another angle: the 2020 ADA guidelines mention that for patients with type 2 diabetes who are obese, weight management is a critical part of treatment. ",
            "source": "response"
        },
        {
            "id": "resp39",
            "annotation": false,
            "start": 4492,
            "end": 4583,
            "label": "fact",
            "text": "They recommend that pharmacotherapy for weight loss should be considered in such patients. ",
            "source": "response"
        },
        {
            "id": "resp40",
            "annotation": false,
            "start": 4583,
            "end": 4648,
            "label": "fact",
            "text": "However, the first-line for glycemic control is still metformin. ",
            "source": "response"
        },
        {
            "id": "resp41",
            "annotation": false,
            "start": 4648,
            "end": 4752,
            "label": "reasoning",
            "text": "But if the patient needs both glycemic control and weight loss, then GLP-1 agonists might be preferred. ",
            "source": "response"
        },
        {
            "id": "resp42",
            "annotation": false,
            "start": 4752,
            "end": 4883,
            "label": "reasoning",
            "text": "So perhaps in the context of obesity, GLP-1 agonists are considered first-line alongside metformin, or even instead of metformin.\n\n",
            "source": "response"
        },
        {
            "id": "resp43",
            "annotation": false,
            "start": 4883,
            "end": 4991,
            "label": "restatement",
            "text": "Wait, the ADA's 2020 guidelines state that metformin remains the first-line therapy unless contraindicated. ",
            "source": "response"
        },
        {
            "id": "resp44",
            "annotation": false,
            "start": 4991,
            "end": 5133,
            "label": "fact",
            "text": "However, in patients where weight loss is a priority, GLP-1 receptor agonists or SGLT2 inhibitors may be appropriate even as initial therapy. ",
            "source": "response"
        },
        {
            "id": "resp45",
            "annotation": false,
            "start": 5133,
            "end": 5364,
            "label": "reasoning",
            "text": "So maybe the answer is that for patients with type 2 diabetes and obesity, the first-line drug is metformin, but GLP-1 agonists are recommended as first-line in conjunction with metformin or when weight loss is a primary concern.\n\n",
            "source": "response"
        },
        {
            "id": "resp46",
            "annotation": false,
            "start": 5364,
            "end": 5526,
            "label": "reasoning",
            "text": "Alternatively, some guidelines from other organizations, like the American Association of Clinical Endocrinologists (AACE), might have different recommendations. ",
            "source": "response"
        },
        {
            "id": "resp47",
            "annotation": false,
            "start": 5526,
            "end": 5611,
            "label": "fact",
            "text": "For example, AACE guidelines might prioritize GLP-1 agonists more in obese patients. ",
            "source": "response"
        },
        {
            "id": "resp48",
            "annotation": false,
            "start": 5611,
            "end": 5708,
            "label": "planning",
            "text": "But the question is as of 2020, so I need to check the most recent guidelines around that time.\n\n",
            "source": "response"
        },
        {
            "id": "resp49",
            "annotation": false,
            "start": 5708,
            "end": 5855,
            "label": "fact",
            "text": "Looking up, ADA 2020 guidelines: For patients with T2D and overweight/obesity, first-line therapy includes lifestyle modifications plus metformin. ",
            "source": "response"
        },
        {
            "id": "resp50",
            "annotation": false,
            "start": 5855,
            "end": 5920,
            "label": "fact",
            "text": "If HbA1c is above target, then adding GLP-1 or SGLT2 inhibitors. ",
            "source": "response"
        },
        {
            "id": "resp51",
            "annotation": false,
            "start": 5920,
            "end": 6029,
            "label": "fact",
            "text": "However, if the patient has compelling needs for weight loss, then GLP-1 agonists may be considered earlier. ",
            "source": "response"
        },
        {
            "id": "resp52",
            "annotation": false,
            "start": 6029,
            "end": 6085,
            "label": "fact",
            "text": "But as first-line, metformin is still the initial drug. ",
            "source": "response"
        },
        {
            "id": "resp53",
            "annotation": false,
            "start": 6085,
            "end": 6191,
            "label": "reasoning",
            "text": "So the answer would be metformin, but with consideration of GLP-1 agonists if weight loss is a priority.\n\n",
            "source": "response"
        },
        {
            "id": "resp54",
            "annotation": false,
            "start": 6191,
            "end": 6224,
            "label": "reflection",
            "text": "But maybe there's a nuance here. ",
            "source": "response"
        },
        {
            "id": "resp55",
            "annotation": false,
            "start": 6224,
            "end": 6312,
            "label": "fact",
            "text": "For example, in patients with high cardiovascular risk, GLP-1 agonists are recommended. ",
            "source": "response"
        },
        {
            "id": "resp56",
            "annotation": false,
            "start": 6312,
            "end": 6388,
            "label": "fact",
            "text": "But for obesity without other comorbidities, metformin is still first-line. ",
            "source": "response"
        },
        {
            "id": "resp57",
            "annotation": false,
            "start": 6388,
            "end": 6478,
            "label": "reasoning",
            "text": "However, given that obesity itself is a comorbidity, perhaps the guidelines have shifted. ",
            "source": "response"
        },
        {
            "id": "resp58",
            "annotation": false,
            "start": 6478,
            "end": 6638,
            "label": "restatement",
            "text": "Wait, ADA 2020 does mention that in patients with type 2 diabetes and obesity, medications that promote weight loss (like GLP-1 agonists) should be considered. ",
            "source": "response"
        },
        {
            "id": "resp59",
            "annotation": false,
            "start": 6638,
            "end": 6700,
            "label": "reflection",
            "text": "But does that mean they are first-line instead of metformin?\n\n",
            "source": "response"
        },
        {
            "id": "resp60",
            "annotation": false,
            "start": 6700,
            "end": 6786,
            "label": "reasoning",
            "text": "Alternatively, maybe the combination of metformin plus a GLP-1 agonist is first-line. ",
            "source": "response"
        },
        {
            "id": "resp61",
            "annotation": false,
            "start": 6786,
            "end": 6847,
            "label": "fact",
            "text": "But typically, first-line refers to the initial monotherapy. ",
            "source": "response"
        },
        {
            "id": "resp62",
            "annotation": false,
            "start": 6847,
            "end": 6920,
            "label": "reasoning",
            "text": "So if the patient is newly diagnosed, the first drug would be metformin. ",
            "source": "response"
        },
        {
            "id": "resp63",
            "annotation": false,
            "start": 6920,
            "end": 6980,
            "label": "reasoning",
            "text": "If they have obesity, then adding a GLP-1 agonist early on. ",
            "source": "response"
        },
        {
            "id": "resp64",
            "annotation": false,
            "start": 6980,
            "end": 7044,
            "label": "restatement",
            "text": "But the question is about the first-line drug, so monotherapy.\n\n",
            "source": "response"
        },
        {
            "id": "resp65",
            "annotation": false,
            "start": 7044,
            "end": 7206,
            "label": "reasoning",
            "text": "Another point: some sources suggest that in obese patients with type 2 diabetes, GLP-1 agonists may be preferred as first-line due to their weight loss benefits. ",
            "source": "response"
        },
        {
            "id": "resp66",
            "annotation": false,
            "start": 7206,
            "end": 7292,
            "label": "fact",
            "text": "However, metformin is cheaper and has a long safety record, so it's still first-line. ",
            "source": "response"
        },
        {
            "id": "resp67",
            "annotation": false,
            "start": 7292,
            "end": 7356,
            "label": "reasoning",
            "text": "But guidelines might differ based on specific patient factors.\n\n",
            "source": "response"
        },
        {
            "id": "resp68",
            "annotation": false,
            "start": 7356,
            "end": 7501,
            "label": "reasoning",
            "text": "In summary, the answer might be that as of 2020, metformin is still the first-line drug for type 2 diabetes, including in patients with obesity. ",
            "source": "response"
        },
        {
            "id": "resp69",
            "annotation": false,
            "start": 7501,
            "end": 7660,
            "label": "reasoning",
            "text": "However, GLP-1 receptor agonists are recommended as first-line in patients where weight loss is a priority or when there's established cardiovascular disease. ",
            "source": "response"
        },
        {
            "id": "resp70",
            "annotation": false,
            "start": 7660,
            "end": 7735,
            "label": "reasoning",
            "text": "But the exact first-line might depend on the specific guidelines followed. ",
            "source": "response"
        },
        {
            "id": "resp71",
            "annotation": false,
            "start": 7735,
            "end": 7907,
            "label": "conclusion",
            "text": "The ADA 2020 Standards of Care state that metformin is first-line, but GLP-1 agonists are preferred if there's a compelling need for weight loss or cardiovascular benefits.",
            "source": "response"
        }
    ],
    "edges": [
        {
            "id": "e0",
            "from_node_id": "ctx0",
            "to_node_id": "resp0",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e1",
            "from_node_id": "resp0",
            "to_node_id": "resp1",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e2",
            "from_node_id": "resp0",
            "to_node_id": "resp2",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e3",
            "from_node_id": "resp1",
            "to_node_id": "resp2",
            "label": "reason:plan-step"
        },
        {
            "id": "e4",
            "from_node_id": "resp1",
            "to_node_id": "resp3",
            "label": "reason:plan-step"
        },
        {
            "id": "e5",
            "from_node_id": "resp2",
            "to_node_id": "resp3",
            "label": "reason:fact-detail"
        },
        {
            "id": "e6",
            "from_node_id": "resp3",
            "to_node_id": "resp4",
            "label": "reason:fact-detail"
        },
        {
            "id": "e7",
            "from_node_id": "resp3",
            "to_node_id": "resp5",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e8",
            "from_node_id": "resp4",
            "to_node_id": "resp5",
            "label": "reason:fact-detail"
        },
        {
            "id": "e9",
            "from_node_id": "resp3",
            "to_node_id": "resp6",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e10",
            "from_node_id": "resp4",
            "to_node_id": "resp6",
            "label": "reason:fact-detail"
        },
        {
            "id": "e11",
            "from_node_id": "resp5",
            "to_node_id": "resp6",
            "label": "evaluate:support"
        },
        {
            "id": "e12",
            "from_node_id": "resp1",
            "to_node_id": "resp7",
            "label": "reason:plan-step"
        },
        {
            "id": "e13",
            "from_node_id": "resp6",
            "to_node_id": "resp7",
            "label": "reason:fact-detail"
        },
        {
            "id": "e14",
            "from_node_id": "resp7",
            "to_node_id": "resp8",
            "label": "reason:fact-detail"
        },
        {
            "id": "e15",
            "from_node_id": "resp8",
            "to_node_id": "resp9",
            "label": "reason:fact-detail"
        },
        {
            "id": "e16",
            "from_node_id": "resp7",
            "to_node_id": "resp10",
            "label": "reason:fact-detail"
        },
        {
            "id": "e17",
            "from_node_id": "resp8",
            "to_node_id": "resp10",
            "label": "reason:fact-detail"
        },
        {
            "id": "e18",
            "from_node_id": "ctx0",
            "to_node_id": "resp11",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e19",
            "from_node_id": "resp0",
            "to_node_id": "resp11",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e20",
            "from_node_id": "resp6",
            "to_node_id": "resp12",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e21",
            "from_node_id": "resp11",
            "to_node_id": "resp12",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e22",
            "from_node_id": "resp11",
            "to_node_id": "resp13",
            "label": "reason:fact-detail"
        },
        {
            "id": "e23",
            "from_node_id": "resp12",
            "to_node_id": "resp13",
            "label": "reason:fact-detail"
        },
        {
            "id": "e24",
            "from_node_id": "resp12",
            "to_node_id": "resp14",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e25",
            "from_node_id": "resp13",
            "to_node_id": "resp14",
            "label": "reason:fact-detail"
        },
        {
            "id": "e26",
            "from_node_id": "resp8",
            "to_node_id": "resp15",
            "label": "reason:concept-example"
        },
        {
            "id": "e27",
            "from_node_id": "resp10",
            "to_node_id": "resp15",
            "label": "reason:concept-example"
        },
        {
            "id": "e28",
            "from_node_id": "resp12",
            "to_node_id": "resp15",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e29",
            "from_node_id": "resp14",
            "to_node_id": "resp15",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e30",
            "from_node_id": "resp3",
            "to_node_id": "resp16",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e31",
            "from_node_id": "resp15",
            "to_node_id": "resp16",
            "label": "evaluate:refute"
        },
        {
            "id": "e32",
            "from_node_id": "resp15",
            "to_node_id": "resp17",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e33",
            "from_node_id": "resp16",
            "to_node_id": "resp17",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e34",
            "from_node_id": "resp15",
            "to_node_id": "resp18",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e35",
            "from_node_id": "resp16",
            "to_node_id": "resp18",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e36",
            "from_node_id": "resp17",
            "to_node_id": "resp18",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e37",
            "from_node_id": "resp12",
            "to_node_id": "resp19",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e38",
            "from_node_id": "resp13",
            "to_node_id": "resp19",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e39",
            "from_node_id": "resp15",
            "to_node_id": "resp19",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e40",
            "from_node_id": "resp16",
            "to_node_id": "resp19",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e41",
            "from_node_id": "resp17",
            "to_node_id": "resp19",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e42",
            "from_node_id": "resp15",
            "to_node_id": "resp20",
            "label": "reason:fact-detail"
        },
        {
            "id": "e43",
            "from_node_id": "resp19",
            "to_node_id": "resp20",
            "label": "reason:plan-step"
        },
        {
            "id": "e44",
            "from_node_id": "resp15",
            "to_node_id": "resp21",
            "label": "reason:fact-detail"
        },
        {
            "id": "e45",
            "from_node_id": "resp16",
            "to_node_id": "resp21",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e46",
            "from_node_id": "resp17",
            "to_node_id": "resp21",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e47",
            "from_node_id": "resp18",
            "to_node_id": "resp21",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e48",
            "from_node_id": "resp16",
            "to_node_id": "resp22",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e49",
            "from_node_id": "resp18",
            "to_node_id": "resp22",
            "label": "reason:plan-step"
        },
        {
            "id": "e50",
            "from_node_id": "resp21",
            "to_node_id": "resp22",
            "label": "reason:plan-step"
        },
        {
            "id": "e51",
            "from_node_id": "ctx0",
            "to_node_id": "resp23",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e52",
            "from_node_id": "resp11",
            "to_node_id": "resp23",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e53",
            "from_node_id": "resp19",
            "to_node_id": "resp24",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e54",
            "from_node_id": "resp22",
            "to_node_id": "resp24",
            "label": "plan:plan-alternative"
        },
        {
            "id": "e55",
            "from_node_id": "resp23",
            "to_node_id": "resp24",
            "label": "plan:frontier-verify"
        },
        {
            "id": "e56",
            "from_node_id": "resp19",
            "to_node_id": "resp25",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e57",
            "from_node_id": "resp20",
            "to_node_id": "resp25",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e58",
            "from_node_id": "resp24",
            "to_node_id": "resp25",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e59",
            "from_node_id": "resp24",
            "to_node_id": "resp26",
            "label": "reason:plan-step"
        },
        {
            "id": "e60",
            "from_node_id": "resp25",
            "to_node_id": "resp26",
            "label": "reason:plan-step"
        },
        {
            "id": "e61",
            "from_node_id": "resp20",
            "to_node_id": "resp27",
            "label": "reason:fact-detail"
        },
        {
            "id": "e62",
            "from_node_id": "resp26",
            "to_node_id": "resp27",
            "label": "reason:fact-detail"
        },
        {
            "id": "e63",
            "from_node_id": "resp24",
            "to_node_id": "resp28",
            "label": "reason:plan-step"
        },
        {
            "id": "e64",
            "from_node_id": "resp27",
            "to_node_id": "resp28",
            "label": "reason:fact-detail"
        },
        {
            "id": "e65",
            "from_node_id": "resp26",
            "to_node_id": "resp29",
            "label": "reason:fact-detail"
        },
        {
            "id": "e66",
            "from_node_id": "resp27",
            "to_node_id": "resp29",
            "label": "reason:fact-detail"
        },
        {
            "id": "e67",
            "from_node_id": "resp28",
            "to_node_id": "resp29",
            "label": "reason:fact-detail"
        },
        {
            "id": "e68",
            "from_node_id": "resp15",
            "to_node_id": "resp30",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e69",
            "from_node_id": "resp18",
            "to_node_id": "resp30",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e70",
            "from_node_id": "resp22",
            "to_node_id": "resp30",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e71",
            "from_node_id": "resp26",
            "to_node_id": "resp30",
            "label": "reason:fact-detail"
        },
        {
            "id": "e72",
            "from_node_id": "resp28",
            "to_node_id": "resp30",
            "label": "reason:fact-detail"
        },
        {
            "id": "e73",
            "from_node_id": "resp22",
            "to_node_id": "resp31",
            "label": "reason:plan-step"
        },
        {
            "id": "e74",
            "from_node_id": "resp28",
            "to_node_id": "resp31",
            "label": "reason:fact-detail"
        },
        {
            "id": "e75",
            "from_node_id": "resp29",
            "to_node_id": "resp31",
            "label": "reason:fact-detail"
        },
        {
            "id": "e76",
            "from_node_id": "resp30",
            "to_node_id": "resp31",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e77",
            "from_node_id": "resp26",
            "to_node_id": "resp32",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e78",
            "from_node_id": "resp27",
            "to_node_id": "resp32",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e79",
            "from_node_id": "resp28",
            "to_node_id": "resp32",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e80",
            "from_node_id": "resp29",
            "to_node_id": "resp32",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e81",
            "from_node_id": "resp30",
            "to_node_id": "resp33",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e82",
            "from_node_id": "resp31",
            "to_node_id": "resp33",
            "label": "reason:concept-example"
        },
        {
            "id": "e83",
            "from_node_id": "resp32",
            "to_node_id": "resp33",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e84",
            "from_node_id": "resp8",
            "to_node_id": "resp34",
            "label": "reason:fact-detail"
        },
        {
            "id": "e85",
            "from_node_id": "resp9",
            "to_node_id": "resp34",
            "label": "reason:fact-detail"
        },
        {
            "id": "e86",
            "from_node_id": "resp31",
            "to_node_id": "resp34",
            "label": "reason:fact-detail"
        },
        {
            "id": "e87",
            "from_node_id": "resp34",
            "to_node_id": "resp35",
            "label": "reason:fact-detail"
        },
        {
            "id": "e88",
            "from_node_id": "resp30",
            "to_node_id": "resp36",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e89",
            "from_node_id": "resp31",
            "to_node_id": "resp36",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e90",
            "from_node_id": "resp32",
            "to_node_id": "resp36",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e91",
            "from_node_id": "resp34",
            "to_node_id": "resp36",
            "label": "reason:concept-example"
        },
        {
            "id": "e92",
            "from_node_id": "resp35",
            "to_node_id": "resp36",
            "label": "reason:concept-example"
        },
        {
            "id": "e93",
            "from_node_id": "resp32",
            "to_node_id": "resp37",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e94",
            "from_node_id": "resp36",
            "to_node_id": "resp37",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e95",
            "from_node_id": "resp28",
            "to_node_id": "resp38",
            "label": "reason:fact-detail"
        },
        {
            "id": "e96",
            "from_node_id": "resp29",
            "to_node_id": "resp38",
            "label": "reason:fact-detail"
        },
        {
            "id": "e97",
            "from_node_id": "resp30",
            "to_node_id": "resp38",
            "label": "reason:fact-detail"
        },
        {
            "id": "e98",
            "from_node_id": "resp30",
            "to_node_id": "resp39",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e99",
            "from_node_id": "resp36",
            "to_node_id": "resp39",
            "label": "reason:concept-example"
        },
        {
            "id": "e100",
            "from_node_id": "resp38",
            "to_node_id": "resp39",
            "label": "reason:fact-detail"
        },
        {
            "id": "e101",
            "from_node_id": "resp26",
            "to_node_id": "resp40",
            "label": "reason:fact-detail"
        },
        {
            "id": "e102",
            "from_node_id": "resp32",
            "to_node_id": "resp40",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e103",
            "from_node_id": "resp30",
            "to_node_id": "resp41",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e104",
            "from_node_id": "resp31",
            "to_node_id": "resp41",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e105",
            "from_node_id": "resp32",
            "to_node_id": "resp41",
            "label": "evaluate:refute"
        },
        {
            "id": "e106",
            "from_node_id": "resp36",
            "to_node_id": "resp41",
            "label": "reason:concept-example"
        },
        {
            "id": "e107",
            "from_node_id": "resp39",
            "to_node_id": "resp41",
            "label": "reason:fact-detail"
        },
        {
            "id": "e108",
            "from_node_id": "resp30",
            "to_node_id": "resp42",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e109",
            "from_node_id": "resp31",
            "to_node_id": "resp42",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e110",
            "from_node_id": "resp36",
            "to_node_id": "resp42",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e111",
            "from_node_id": "resp41",
            "to_node_id": "resp42",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e112",
            "from_node_id": "resp26",
            "to_node_id": "resp43",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e113",
            "from_node_id": "resp32",
            "to_node_id": "resp43",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e114",
            "from_node_id": "resp40",
            "to_node_id": "resp43",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e115",
            "from_node_id": "resp40",
            "to_node_id": "resp44",
            "label": "reason:fact-detail"
        },
        {
            "id": "e116",
            "from_node_id": "resp41",
            "to_node_id": "resp44",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e117",
            "from_node_id": "resp42",
            "to_node_id": "resp44",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e118",
            "from_node_id": "resp32",
            "to_node_id": "resp45",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e119",
            "from_node_id": "resp40",
            "to_node_id": "resp45",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e120",
            "from_node_id": "resp42",
            "to_node_id": "resp45",
            "label": "evaluate:support"
        },
        {
            "id": "e121",
            "from_node_id": "resp44",
            "to_node_id": "resp45",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e122",
            "from_node_id": "resp32",
            "to_node_id": "resp46",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e123",
            "from_node_id": "resp44",
            "to_node_id": "resp46",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e124",
            "from_node_id": "resp45",
            "to_node_id": "resp46",
            "label": "plan:plan-alternative"
        },
        {
            "id": "e125",
            "from_node_id": "resp45",
            "to_node_id": "resp47",
            "label": "reason:concept-example"
        },
        {
            "id": "e126",
            "from_node_id": "resp46",
            "to_node_id": "resp47",
            "label": "reason:fact-detail"
        },
        {
            "id": "e127",
            "from_node_id": "resp24",
            "to_node_id": "resp48",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e128",
            "from_node_id": "resp25",
            "to_node_id": "resp48",
            "label": "plan:plan-nextplan"
        },
        {
            "id": "e129",
            "from_node_id": "resp26",
            "to_node_id": "resp48",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e130",
            "from_node_id": "resp27",
            "to_node_id": "resp48",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e131",
            "from_node_id": "resp44",
            "to_node_id": "resp48",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e132",
            "from_node_id": "resp44",
            "to_node_id": "resp49",
            "label": "reason:fact-detail"
        },
        {
            "id": "e133",
            "from_node_id": "resp45",
            "to_node_id": "resp49",
            "label": "reason:fact-detail"
        },
        {
            "id": "e134",
            "from_node_id": "resp48",
            "to_node_id": "resp49",
            "label": "reason:plan-step"
        },
        {
            "id": "e135",
            "from_node_id": "resp48",
            "to_node_id": "resp50",
            "label": "reason:plan-step"
        },
        {
            "id": "e136",
            "from_node_id": "resp49",
            "to_node_id": "resp50",
            "label": "reason:fact-detail"
        },
        {
            "id": "e137",
            "from_node_id": "resp44",
            "to_node_id": "resp51",
            "label": "reason:fact-detail"
        },
        {
            "id": "e138",
            "from_node_id": "resp45",
            "to_node_id": "resp51",
            "label": "reason:fact-detail"
        },
        {
            "id": "e139",
            "from_node_id": "resp49",
            "to_node_id": "resp51",
            "label": "reason:fact-detail"
        },
        {
            "id": "e140",
            "from_node_id": "resp50",
            "to_node_id": "resp51",
            "label": "reason:fact-detail"
        },
        {
            "id": "e141",
            "from_node_id": "resp43",
            "to_node_id": "resp52",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e142",
            "from_node_id": "resp45",
            "to_node_id": "resp52",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e143",
            "from_node_id": "resp49",
            "to_node_id": "resp52",
            "label": "reason:fact-detail"
        },
        {
            "id": "e144",
            "from_node_id": "resp50",
            "to_node_id": "resp52",
            "label": "reason:fact-detail"
        },
        {
            "id": "e145",
            "from_node_id": "resp51",
            "to_node_id": "resp52",
            "label": "reason:fact-detail"
        },
        {
            "id": "e146",
            "from_node_id": "resp44",
            "to_node_id": "resp53",
            "label": "reason:fact-detail"
        },
        {
            "id": "e147",
            "from_node_id": "resp45",
            "to_node_id": "resp53",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e148",
            "from_node_id": "resp50",
            "to_node_id": "resp53",
            "label": "reason:fact-detail"
        },
        {
            "id": "e149",
            "from_node_id": "resp51",
            "to_node_id": "resp53",
            "label": "reason:fact-detail"
        },
        {
            "id": "e150",
            "from_node_id": "resp52",
            "to_node_id": "resp53",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e151",
            "from_node_id": "resp44",
            "to_node_id": "resp54",
            "label": "reason:fact-detail"
        },
        {
            "id": "e152",
            "from_node_id": "resp45",
            "to_node_id": "resp54",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e153",
            "from_node_id": "resp53",
            "to_node_id": "resp54",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e154",
            "from_node_id": "resp27",
            "to_node_id": "resp55",
            "label": "reason:fact-detail"
        },
        {
            "id": "e155",
            "from_node_id": "resp44",
            "to_node_id": "resp55",
            "label": "reason:fact-detail"
        },
        {
            "id": "e156",
            "from_node_id": "resp51",
            "to_node_id": "resp55",
            "label": "reason:fact-detail"
        },
        {
            "id": "e157",
            "from_node_id": "resp52",
            "to_node_id": "resp56",
            "label": "reason:fact-detail"
        },
        {
            "id": "e158",
            "from_node_id": "resp53",
            "to_node_id": "resp56",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e159",
            "from_node_id": "resp44",
            "to_node_id": "resp57",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e160",
            "from_node_id": "resp45",
            "to_node_id": "resp57",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e161",
            "from_node_id": "resp53",
            "to_node_id": "resp57",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e162",
            "from_node_id": "resp56",
            "to_node_id": "resp57",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e163",
            "from_node_id": "ctx0",
            "to_node_id": "resp58",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e164",
            "from_node_id": "resp44",
            "to_node_id": "resp58",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e165",
            "from_node_id": "resp45",
            "to_node_id": "resp58",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e166",
            "from_node_id": "resp53",
            "to_node_id": "resp59",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e167",
            "from_node_id": "resp56",
            "to_node_id": "resp59",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e168",
            "from_node_id": "resp58",
            "to_node_id": "resp59",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e169",
            "from_node_id": "resp45",
            "to_node_id": "resp60",
            "label": "reason:plan-step"
        },
        {
            "id": "e170",
            "from_node_id": "resp46",
            "to_node_id": "resp60",
            "label": "reason:plan-step"
        },
        {
            "id": "e171",
            "from_node_id": "resp53",
            "to_node_id": "resp60",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e172",
            "from_node_id": "resp57",
            "to_node_id": "resp60",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e173",
            "from_node_id": "resp59",
            "to_node_id": "resp60",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e174",
            "from_node_id": "resp53",
            "to_node_id": "resp61",
            "label": "reason:fact-detail"
        },
        {
            "id": "e175",
            "from_node_id": "resp58",
            "to_node_id": "resp61",
            "label": "reason:fact-detail"
        },
        {
            "id": "e176",
            "from_node_id": "resp59",
            "to_node_id": "resp61",
            "label": "reason:fact-detail"
        },
        {
            "id": "e177",
            "from_node_id": "resp60",
            "to_node_id": "resp61",
            "label": "reason:fact-detail"
        },
        {
            "id": "e178",
            "from_node_id": "resp52",
            "to_node_id": "resp62",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e179",
            "from_node_id": "resp53",
            "to_node_id": "resp62",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e180",
            "from_node_id": "resp56",
            "to_node_id": "resp62",
            "label": "reason:fact-detail"
        },
        {
            "id": "e181",
            "from_node_id": "resp61",
            "to_node_id": "resp62",
            "label": "reason:concept-example"
        },
        {
            "id": "e182",
            "from_node_id": "resp51",
            "to_node_id": "resp63",
            "label": "reason:fact-detail"
        },
        {
            "id": "e183",
            "from_node_id": "resp52",
            "to_node_id": "resp63",
            "label": "reason:fact-detail"
        },
        {
            "id": "e184",
            "from_node_id": "resp60",
            "to_node_id": "resp63",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e185",
            "from_node_id": "resp62",
            "to_node_id": "resp63",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e186",
            "from_node_id": "ctx0",
            "to_node_id": "resp64",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e187",
            "from_node_id": "resp23",
            "to_node_id": "resp64",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e188",
            "from_node_id": "resp61",
            "to_node_id": "resp64",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e189",
            "from_node_id": "resp30",
            "to_node_id": "resp65",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e190",
            "from_node_id": "resp31",
            "to_node_id": "resp65",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e191",
            "from_node_id": "resp32",
            "to_node_id": "resp65",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e192",
            "from_node_id": "resp36",
            "to_node_id": "resp65",
            "label": "reason:concept-example"
        },
        {
            "id": "e193",
            "from_node_id": "resp42",
            "to_node_id": "resp65",
            "label": "reason:concept-example"
        },
        {
            "id": "e194",
            "from_node_id": "resp45",
            "to_node_id": "resp65",
            "label": "reason:concept-example"
        },
        {
            "id": "e195",
            "from_node_id": "resp53",
            "to_node_id": "resp65",
            "label": "reason:concept-example"
        },
        {
            "id": "e196",
            "from_node_id": "resp57",
            "to_node_id": "resp65",
            "label": "reason:concept-example"
        },
        {
            "id": "e197",
            "from_node_id": "resp60",
            "to_node_id": "resp65",
            "label": "reason:concept-example"
        },
        {
            "id": "e198",
            "from_node_id": "resp52",
            "to_node_id": "resp66",
            "label": "reason:fact-detail"
        },
        {
            "id": "e199",
            "from_node_id": "resp53",
            "to_node_id": "resp66",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e200",
            "from_node_id": "resp56",
            "to_node_id": "resp66",
            "label": "reason:fact-detail"
        },
        {
            "id": "e201",
            "from_node_id": "resp0",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e202",
            "from_node_id": "resp1",
            "to_node_id": "resp67",
            "label": "reason:plan-step"
        },
        {
            "id": "e203",
            "from_node_id": "resp2",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e204",
            "from_node_id": "resp3",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e205",
            "from_node_id": "resp4",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e206",
            "from_node_id": "resp5",
            "to_node_id": "resp67",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e207",
            "from_node_id": "resp6",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e208",
            "from_node_id": "resp7",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e209",
            "from_node_id": "resp8",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e210",
            "from_node_id": "resp9",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e211",
            "from_node_id": "resp10",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e212",
            "from_node_id": "resp11",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e213",
            "from_node_id": "resp12",
            "to_node_id": "resp67",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e214",
            "from_node_id": "resp13",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e215",
            "from_node_id": "resp14",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e216",
            "from_node_id": "resp15",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e217",
            "from_node_id": "resp16",
            "to_node_id": "resp67",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e218",
            "from_node_id": "resp17",
            "to_node_id": "resp67",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e219",
            "from_node_id": "resp18",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e220",
            "from_node_id": "resp19",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e221",
            "from_node_id": "resp20",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e222",
            "from_node_id": "resp21",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e223",
            "from_node_id": "resp22",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e224",
            "from_node_id": "resp23",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e225",
            "from_node_id": "resp24",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e226",
            "from_node_id": "resp25",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e227",
            "from_node_id": "resp26",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e228",
            "from_node_id": "resp27",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e229",
            "from_node_id": "resp28",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e230",
            "from_node_id": "resp29",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e231",
            "from_node_id": "resp30",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e232",
            "from_node_id": "resp31",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e233",
            "from_node_id": "resp32",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e234",
            "from_node_id": "resp33",
            "to_node_id": "resp67",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e235",
            "from_node_id": "resp34",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e236",
            "from_node_id": "resp35",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e237",
            "from_node_id": "resp36",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e238",
            "from_node_id": "resp37",
            "to_node_id": "resp67",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e239",
            "from_node_id": "resp38",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e240",
            "from_node_id": "resp39",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e241",
            "from_node_id": "resp40",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e242",
            "from_node_id": "resp41",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e243",
            "from_node_id": "resp42",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e244",
            "from_node_id": "resp43",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e245",
            "from_node_id": "resp44",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e246",
            "from_node_id": "resp45",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e247",
            "from_node_id": "resp46",
            "to_node_id": "resp67",
            "label": "reason:concept-example"
        },
        {
            "id": "e248",
            "from_node_id": "resp47",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e249",
            "from_node_id": "resp48",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e250",
            "from_node_id": "resp49",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e251",
            "from_node_id": "resp50",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e252",
            "from_node_id": "resp51",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e253",
            "from_node_id": "resp52",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e254",
            "from_node_id": "resp53",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e255",
            "from_node_id": "resp54",
            "to_node_id": "resp67",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e256",
            "from_node_id": "resp55",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e257",
            "from_node_id": "resp56",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e258",
            "from_node_id": "resp57",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e259",
            "from_node_id": "resp58",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e260",
            "from_node_id": "resp59",
            "to_node_id": "resp67",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e261",
            "from_node_id": "resp60",
            "to_node_id": "resp67",
            "label": "reason:concept-example"
        },
        {
            "id": "e262",
            "from_node_id": "resp61",
            "to_node_id": "resp67",
            "label": "reason:fact-detail"
        },
        {
            "id": "e263",
            "from_node_id": "resp62",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e264",
            "from_node_id": "resp63",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e265",
            "from_node_id": "resp64",
            "to_node_id": "resp67",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e266",
            "from_node_id": "resp65",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e267",
            "from_node_id": "resp66",
            "to_node_id": "resp67",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e268",
            "from_node_id": "resp52",
            "to_node_id": "resp68",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e269",
            "from_node_id": "resp53",
            "to_node_id": "resp68",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e270",
            "from_node_id": "resp56",
            "to_node_id": "resp68",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e271",
            "from_node_id": "resp62",
            "to_node_id": "resp68",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e272",
            "from_node_id": "resp64",
            "to_node_id": "resp68",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e273",
            "from_node_id": "resp66",
            "to_node_id": "resp68",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e274",
            "from_node_id": "resp44",
            "to_node_id": "resp69",
            "label": "reason:fact-detail"
        },
        {
            "id": "e275",
            "from_node_id": "resp45",
            "to_node_id": "resp69",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e276",
            "from_node_id": "resp51",
            "to_node_id": "resp69",
            "label": "reason:fact-detail"
        },
        {
            "id": "e277",
            "from_node_id": "resp66",
            "to_node_id": "resp69",
            "label": "reason:fact-detail"
        },
        {
            "id": "e278",
            "from_node_id": "resp68",
            "to_node_id": "resp69",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e279",
            "from_node_id": "resp46",
            "to_node_id": "resp70",
            "label": "reason:plan-step"
        },
        {
            "id": "e280",
            "from_node_id": "resp67",
            "to_node_id": "resp70",
            "label": "evaluate:uncertainty"
        },
        {
            "id": "e281",
            "from_node_id": "resp68",
            "to_node_id": "resp70",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e282",
            "from_node_id": "resp69",
            "to_node_id": "resp70",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e283",
            "from_node_id": "resp32",
            "to_node_id": "resp71",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e284",
            "from_node_id": "resp45",
            "to_node_id": "resp71",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e285",
            "from_node_id": "resp53",
            "to_node_id": "resp71",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e286",
            "from_node_id": "resp68",
            "to_node_id": "resp71",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e287",
            "from_node_id": "resp69",
            "to_node_id": "resp71",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e288",
            "from_node_id": "resp70",
            "to_node_id": "resp71",
            "label": "reason:stmt-restatement"
        }
    ]
}